因塞特医疗宣布，其产品Opzelura®（芦可替尼）乳膏在治疗成人中度特应性皮炎方面，已获得欧洲药品管理局人用药品委员会（CHMP）的积极意见。这一进展为Opzelura®在欧盟市场的获批上市铺平了道路，有望为患者提供一种新的局部治疗选择。
因塞特医疗宣布，其产品Opzelura®（芦可替尼）乳膏在治疗成人中度特应性皮炎方面，已获得欧洲药品管理局人用药品委员会（CHMP）的积极意见。这一进展为Opzelura®在欧盟市场的获批上市铺平了道路，有望为患者提供一种新的局部治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.